Xiuning Le/X
Dec 2, 2024, 20:05
Xiuning Le: RTK fusion-mediated resistance to EGFR-TKI in EGFR-mutated NSCLC
Xiuning Le, Deputy Section Chief of Thoracic Medical Oncology at MD Anderson Cancer Center, shared a post on X:
“New Online JTO and JTO CRR RTK fusion-mediated resistance to EGFR-TKI in EGFR-mutated NSCLC: a multi-center analysis.
ALK (43%) and RET (36%) are most common.
EGFR-RTK dual inhibition has an ORR 24% and DCR 80% with manageable toxicities.”
Authors: Yang Xia, Kaiwen Wang, Jing Zhao, Zhaohui Arter, Yongchang Zhang, Jiaqi Zhou, Yuefei Lu, Liang Zeng, Robyn Du, Jennifer A. Owens, Yasir Y. Elamin, Carl M. Gay, Ferdinandos Skoulidis, Anne S. Tsao, Charles Lu, Tina Cascone, Don L. Gibbons, Jianjun Zhang, Olivia Chen, Kevin KS. Mok, Misako Nagasaka, Wen Li, John V. Heymach, Sai-Hong Ignatius Ou, Molly Li, Xiuning Le
Anne S. Tsao
cancer
Carl M. Gay
Charles Lu
Don L. Gibbons
Ferdinandos Skoulidis
Jennifer A. Owens
Jianjun Zhang
Jiaqi Zhou
Jing Zhao
John V. Heymach
JTO
JTO CRR
Kaiwen Wang
Kevin KS. Mok
Liang Zeng
MD Anderson Cancer Center
Misako Nagasaka
Molly Li
NSCLC
Olivia Chen
OncoDaily
Oncology
Robyn Du
Sai-Hong Ignatius Ou
Tina Cascone
Wen Li
Xiuning Le
Yang Xia
Yasir Y. Elamin
Yongchang Zhang
Yuefei Lu
Zhaohui Arter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 2, 2024, 19:24
Dec 2, 2024, 19:20
Dec 2, 2024, 19:16
Dec 2, 2024, 19:06
Dec 2, 2024, 19:02
Dec 2, 2024, 18:24
Dec 2, 2024, 18:18